Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration

Eye

Volumn 26, Issue 4, 2012, Pages 557-563

  Jackson, T L ^a,b   Kirkpatrick, L ^b   Tang, G ^c   Prasad, S ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Quorum Consulting   (United States)

^d ARROWE PARK HOSPITAL   (United Kingdom)

Author keywords

bevacizumab; cost; epimacular brachytherapy; health economics; neovascular age related macular degeneration; ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; BRACHYTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION;

EID: 84859758565     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.351     Document Type: Article

References (15)

1. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006; 6: 58.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. NICE Technology Appraisal Guidance 155: ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.
5. IMS data (http://www.imshealth.com).
6. Minassian DC, Reidy A, Lightstone A, Desai P. Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Brit J Ophth 2011; 95(10): 1433-1436.
7. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med 2011; 364(20): 1897-1908.
8. Ávila M, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Brit J Ophth 2009; 93: 305-309.
9. Ávila M, Farah ME, Santos A, Carla L, Fuji G, Rossi J et al. Three year safety and visual acuity results of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 2012; 32: 10-18.
10. Dugel P, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J et al. Macular EpiRetinal brachytherapy in Treated AGE-related macular degeneration (MERITAGE): 12 month safety and efficacy results. Ophthalmology (in press).
11. NICE Technology Appraisal Guidance 155: ranibizumab and pegaptanib for age-remacular degeneration. Costing template and report - implementing NICE guidance, August 2008.
12. 2011-12 PbR Tariff Information (http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH-122717) .
13. MHP. The Path to GP Commissioning. MHP: London, 2011.
14. The Royal College of Ophthalmologists. Commissioning contemporary AMD services: a guide for commissioners and clinicians, July 2007.
15. Jackson TL, Kirkpatrick L. Cost comparison of ranibizumab and bevacizumab. BMJ 2011; 23: 343:d5058.